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Purpose: The aim of this study was to assess the uroflowmetry data in a large population 
of asymptomatic Brazilian men submitted to a health check up program and their corre-
lation to IPSS and prostate size.
Materials and Methods: Asymptomatic men underwent a health check-up program be-
tween January and December 2012. The inclusion criteria were men between 40 and 70 
years, IPSS ≤ 7, without bladder, prostate, urethral surgery, neurological diseases, urinary 
tract infection, PSA < 4.0 ng/dL and urinary volume higher than 150 mL. Urological 
assessment consisted of clinical history, IPSS, digital rectal examination (DRE), prostate 
specific antigen (PSA), urinalysis, ultrasonography and uroflowmetry.
Results: A total of 1041 asymptomatic men were included in this study. The average 
age was 49 years and average maximum flow rate was 17.4 mL/s. In spite of IPSS and 
prostate size increase with aging, they had a weak correlation with Qmax cutoffs (10 mL/s 
and 15 mL/s). A total of 85 men (8.3%) had more than 60 years, and even in this group, 
Qmax was higher than 15 mL/s. Out of 1041 men, 117 had IPSS less than 8 and Qmax less 
than 10 mL/s.
Conclusions: In asymptomatic men there is a weak correlation between IPSS, prostate 
size and uroflowmetric data. The establishment of different normal cutoffs seems to be 
complicated and uroflowmetry data should be interpreted with caution in order to avoid 
misdiagnosis.
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INTRODUCTION
 Most men have a progressive prostate 
enlargement after fourth decade. The main con-
sequence of benign prostate hyperplasia (BPH) is 
bladder outlet obstruction (BOO), which is cha-
racterized by high bladder pressure and low flow 
rates. The natural history of BPH is not well es-
tablished and the long-term consequence of BOO 
remains unclear (1,2).
 The assessment of prostatic symptoms 
usually is performed with the International Pros-
tate Symptom Score (IPSS). Regarding prostate 
symptoms, asymptomatic men are those with IPSS 
less than 8. Routinely, uroflowmetry is not indica-
ted in this specific population.
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 Uroflowmetry is a non-invasive method 
that may help the urologist to diagnose bladder 
outlet obstruction. However, it is not able to dis-
tinguish BOO and detrusor underactivity (DUA). 
Both bladder dysfunctions can be characterized 
by low maximum flow rate (Qmax) (1,2).
 Likewise men with BOO, asymptomatic 
men also may have low urinary maximum flow 
rate. For this reason, Qmax in men with or without 
symptoms should be interpreted with caution. 
There is a lack of studies in the literature in this 
specific population (3).
 The aim of this study was to assess the 
uroflowmetry data in a large population of 
asymptomatic Brazilian men submitted to a heal-
th check up program and their correlation it with 
IPSS and prostate size.
MATERIALS E METHODS
 Local Ethical Committee approved the stu-
dy and all subjects filled out a written informed 
consent. This study was performed in asympto-
matic men submitted to a health check-up pro-
gram between January and December 2012. A 
multidisciplinary team composed by general cli-
nicians, urologists, ophthalmologists, dermatolo-
gists, nutritionists and physiotherapists, evalua-
ted patients. Urological assessment consisted of 
clinical history, IPSS, digital rectal examination 
(DRE), prostate specific antigen (PSA), urinalysis, 
ultrasonography and uroflowmetry.
The inclusion criteria were men between 
40 and 70 years, IPSS ≤ 7, without bladder, pros-
tate, urethral surgery, neurological diseases, uri-
nary tract infection, PSA < 4.0 ng/dL and urinary 
volume higher than 150 mL.
 Uroflowmetry and ultrasonography for 
post-void residual urine measurement (PVR) were 
performed during the urological evaluation. PSA 
and urinalysis were collected on the same day 
and before starting the check up.
 Data was analyzed using Statistical Pa-
ckage for Social Sciences (SPSS) version 8.0 for 
Windows. Pearson’s linear correlation coefficient 
was calculated to estimate the correlation be-
tween numeric variables and multiple linear re-
gressions to investigate the association between 
uroflowmetry parameters, clinical and ultrasound 
data. The Pearson’s Chi-Square was performed to 
compare numeric variables. It was considered sta-
tistically significant p values ≤ 0.05.
RESULTS
 Out of 2880 men, 1041 asymptomatic 
men with mean age of 49 ± 6.9 years old 
(range 40 to 70) were included in this study. 
Demographics, IPSS, prostate size and uro-
flowmetry data can be seen on Table-1.
 Men were categorized into three diffe-
rent aging groups (40 to 50, 51 to 60 and 61 
to 70). The older men had higher IPSS, prostate 
size, flow time and micturition time than youn-
ger men (p = 0.001, p = 0.001, p = 0.001 and p 
= 0.001 respectively). On the other hand Qmax 
and Qmed were higher in younger men. Hesita-
tion time, PVR and maximum flow time were 
not statistic significant (p = 0.31, p = 0.31 and 
p = 0.11 respectively). Prostate size, IPSS, post-
-void residual urine and uroflowmetry data in 
the three groups can be observed on Table-2.
 A second analysis was performed com-
paring the men with Qmax > 15 mL/s and Qmax < 
15 mL/s. A total of 424 men (40.7%) with ave-
rage age 50.9 years had Qmax < 15 mL/s, whereas 
617 men (60.3%) with average age 48.8 years 
had Qmax > 15 mL/s. The Qmax cutoff 15 mL/s had 
a weak correlation with aging, IPSS and prosta-
te size on asymptomatic men. These data can be 
observed on Table-3.
 A further analysis was performed in or-
der to correlate the clinical data with lower Qmax 
cutoff (< 10 mL/s). A total of 117 men (11.2%) 
had Qmax less than 10 mL/s and IPSS less than 8. 
The average age of this specific population was 
55.5 years old. Older men had higher IPSS and 
prostate size, however the average Qmax and Qmed 
were not correlated with aging when we con-
sidered only men with Qmax less than 10 mL/s. 
These data can be observed on Table-4.
DISCUSSION
 To our knowledge, this study is the first 
one to assess uroflow, IPSS and prostate size in a 
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Table 1 - Demographics and uroflowmetry data of 1041 men submitted to a health check up program.
Mean ± sd Median (range)
Age (years) 49 ± 6.9 49 (40 - 70)
IPSS 1.9 ± 0.8 1.5 (1 - 7)
Prostate Size (g) 26.6 ± 9.0 25 (10 - 90)
Voided Volume (mL) 370 ± 161 302 (300 - 500)
Post-void residual Urine (mL) 14 ± 10 6 (0 - 187)
Hesitation time (s) 9.2 ± 5.9 8 (3 - 60)
Flow time (s) 34.5 ± 17.8 31 (9 - 73)
Total voided time (mL) 44.3 ± 34.6 40 (20 - 153)
Maximum flow time (s) 11.3 ± 7.4 10 (5 - 21)
Qmax (mL/s) 17.4 ± 7.4 16.3 (8 - 39)
Qmed (mL/s) 11.9 ± 3.3 10.2 (7 - 23)
IPSS = International Prostate Symptom Score; Qmax = maximum flow rate; Qmed: average flow rate; sd = standard deviation
Table 2 - IPSS, prostate size and uroflow data on three different aging groups.
40-50 years 50-60 years 60-70 years p
Subjects 620 (59.5%) 336 (32.2%) 85 (8.3%)
IPSS 1.0 ± 0.5 2.5 ± 1 5.7 ± 3 0.001
Prostate size (grams) 23 ± 6.4 29 ± 9.5 35 ± 14 0.001
Voided volume (mL) 347 ± 150 335 ± 140 304 ± 165 0.01
Post-void residual urine (mL) 11.5 ± 9 19.1 ± 7 15.6 ± 5 0.31
Hesitation time (s) 9.2 ± 6 9.1 ± 5.4 9.6 ± 5.8 0.31
Flow time (mL/s) 32.8 ± 16 36.5 ± 17 40 ± 20 0.001
Micturition time (s) 43.1 ± 20 45.6 ± 19 49.8 ± 24 0.001
Maximum flow time  (s) 11.1 ± 7 11.8 ± 7 11 ± 9 0.11
Qmax (mL/s) 18.3 ± 7 16.4 ± 6.3 15 ± 7.7 0.001
Qmed (mL/s) 13.4 ± 5.2 10.1 ± 5 8.8 ± 4 0.001
IPSS = International Prostate Symptom Score; Qmax = maximum flow rate; Qmed = average flow rate
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Table 3 - IPSS, Prostate size and uroflow data on men with Qmax > 15 mL/s and Qmax < 15 mL/s.
Qmax < 15 mL/s Qmax > 15 mL/s Pearson p
Subjects 424 (40.7%) 617 (60.3%)
Age (years) 50.9 ± 7.6 48.8 ± 6.3 -0.161 0.01
IPSS 3 ± 1 1 ± 0.5 -0.256 0.001
Prostate size (g) 28.3 ± 11 25.4 ± 7.9 -0.166 0.001
Voided volume (mL) 256 ± 127 396 ± 177 0.133 0.001
PVR (mL) 17 ± 7 12 ± 5 -0.132 0.001
Hesitation time(s) 10.5 ± 7.2 8.3 ± 4.7 -0.214 0.003
Flow time(s) 40.2 ± 21 30.6 ± 13.9 -0.267 0.001
Micturition time(s) 50.2 ± 23 40.3 ± 20 -0,149 0.001
Maximum flow time(s) 13.3 ± 9.3 10 ± 5 -0.234 0.001
Average Qmed (mL/s) 6.7 ± 2 15 ± 7 0.130 0.001
Average Qmax (mL/s) 11.42 ± 2.8 21.47 ± 4.1 0.290 0.001
IPSS = International Prostate Symptom Score; Qmax = maximum flow rate; Qmed = average flow rate.
Table 4 - IPSS, prostate size and uroflow data  on men with Qmax < 10 mL/s.
40-50 years 50-60 years 60-70 years p
Subjects 42 (35.8%) 57 (48.7%) 18 (15.3%)
IPSS 1.7 ± 1.5 4.7 ± 3.2 6.4 ± 3.19 0.001
Prostate size (grams) 22.9 ± 8.8 32.6 ± 9.2 39.8 ± 9.2 0.001
Voided volume (mL) 180.7 ± 170 229 ± 172 201 ± 173 0.06
Post-void residual urine (mL) 8.9 ± 22 26.01 ± 22.4 17.4 ± 22 0.05
Hesitation time (s) 15.5 ± 6.07 11.7 ± 5.8 12.1 ± 5.72 0.07
Flow time (mL/s) 38.8 ± 17.9 49.9 ± 17.8 50.8 ± 17.8 0.05
Micturition time (s) 51.9 ± 35.40 62.5 ± 34.6 63 ± 34.8 0.05
Maximum flow time (s) 14.5 ± 7.48 17.8 ± 7.5 11.5 ± 7.54 0.06
Average Qmax (mL/s) 8.37 ± 1.23 8.60 ± 1.15 8.57 ± 0.89 0.43
Average Qmed (mL/s) 4.71 ± 1.27 4.85 ± 3.90 4.42 ± 3.5 0.41
IPSS = International Prostate Symptom Score; Qmax = maximum flow rate; Qmed = average flow rate.
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very specific population of Brazilian asymptoma-
tic men submitted to a health check-up program. 
The IPSS and prostate size increased with aging 
however they had a weak correlation with diffe-
rent Qmax cutoffs (10 mL/s and 15 mL/s). The ave-
rage age of men was 49 years and their average 
maximum flow rate was 17.4 mL/s. A total of 85 
men (8.3%) had more than 60 years, and even in 
this group, Qmax was higher than 15 mL/s. Out of 
1041 men, 117 had IPSS less than 8 and Qmax less 
than 10 mL/s.
The urinary flow is a result of the inte-
raction between detrusor contraction and urethral 
resistance. Low urinary flow may suggest BOO or 
bladder underactivity. Abnormal findings in uro-
flowmetric parameters can suggest voiding dys-
function but the uroflowmetry by itself has a low 
specificity and does not allow the confirmation of 
the etiologic diagnosis. Since there is not a clear 
correlation between symptoms and pressure flow 
studies, an objective parameter is desirable in or-
der to improve the BOO diagnosis. The main issue 
in missing BOO is the potential to develop bladder 
deterioration due to non-treated high urethral re-
sistance (3,4).
The normal value is better determined by 
studying a large number of patients in order to 
evaluate the variable distribution. There is a lack 
of studies describing the uroflowmetry parameters 
in a large population. Many flow-volume nomo-
grams have been constructed. Siroky nomogram 
was based on data of 300 voids of 80 asympto-
matic men and validated it plotting results of 33 
normal men and 53 men with obstructive voiding 
symptoms. Liverpool nomogram was based on a 
large number of observations and underwent pre-
liminary validation using 30 observations of one 
normal volunteer (5,6).
It is not a consensus among urologists to 
perform uroflow and pressure flow studies in the 
routine assessment of men with lower urinary 
tract symptoms. The definition of normality can 
be based on Gaussian or mean ± standard devia-
tion; percentile within a specified range such as 
5% to 95%; culturally desirable; risk factor or an 
individual with no additional risk of disease; diag-
nostic or a range of results beyond which target 
disorder are highly probable and therapeutic or 
a range of results beyond which treatment does 
more good than harm (4,7). We have seen a high 
range of variability in uroflowmetric parameters 
in asymptomatic subjects. Based on our findings, 
we believe that the establishment of normal va-
lues in uroflowmetric parameters in male popula-
tion seems to be complicated.
 Some authors suggested different maxi-
mum flow-rate cut-off values in order to distin-
guish men with or without bladder outlet obstruc-
tion. Higher cut-off maximum flow rates decrease 
the specificity and increase the sensitivity. On the 
other hand lower cut-off maximum flow rates in-
crease the specificity and decrease the sensitivity. 
According to Reynard et al., when Qmax was less 
than 10 mL/s, the test specificity and sensitivity 
were respectively 70% and 47%. Likewise, when 
Qmax was lower than 15 mL/s, the test specifici-
ty and sensitivity were respectively 38% and 82% 
(8,9). In this study 117 men with IPSS less than 
8 had Qmax less than 10 mL/s, which suggest no 
correlation between Qmax and urinary symptoms. 
For this reason, uroflow data should be interpreted 
with caution.
Although symptoms usually stimulate pa-
tients to seek treatment, some studies have shown 
that there is no correlation between symptoms and 
bladder outlet obstruction (10,11). Uroflowmetry 
can be an additional tool for urologists before sur-
gical intervention or treatment failure. Abrams et 
al. demonstrated that 90% of men with maximum 
flow rate lower than 10 mL/s have some degree of 
obstruction. Conversely, 25% to 30% of men with 
decreased flow rate are not obstructed (12).
Urodynamic studies are the most definitive 
tests available to determine the etiology of voi-
ding dysfunction and lower urinary tract symp-
toms. The filling and storage phase can provide 
useful information such as involuntary contrac-
tions, bladder sensation, bladder capacity and 
impaired compliance. Currently, urologists have 
been used pressure-flow nomograms to demons-
trate BOO, however they are essentially based 
on symptomatic patients with low urinary tract 
symptoms due to benign prostatic hyperplasia. 
Walker et al. studied the pressure-flow data in 24 
asymptomatic men with mean age 61 years. The 
peak flow rate and detrusor pressure at maximum 
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peak flow were respectively 17.9 ± 17.5 mL/s and 
49.5 ± 26.2 cm H2O. On pressure flow studies 3 pa-
tients had unequivocal obstruction, 7 were in the 
equivocal area and 14 had no obstruction. These 
findings suggest that even asymptomatic men can 
be obstructed (7).
There are a few data on literature regar-
ding the voiding characteristics of “normal” men. 
Specifically in the developing countries such as 
Brazil, the data registration is inadequate and in 
most cases we have used American or European 
population data as a reference. In this context, 
this study provides a substantial data of a spe-
cific Brazilian men population. In spite of our 
findings, the primary aim of this study was not 
to establish normal uroflowmetric values or cre-
ate uroflow nomograms. We have thought that 
uroflow is an additional tool to evaluate voiding 
dysfunction and should be interpreted linked 
with clinical and ultrasonographic data in order 
to avoid misdiagnosis.
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